Owlet Announces Second Quarter 2026 Financial Results
Key Terms
gaap financial
adjusted ebitda financial
non-gaap financial measures financial
asc 250 regulatory
stock-based compensation financial
Q2 2026 Financial Highlights:
-
Record Q2 Revenue of
, up$33.9 million 29.9% from Q2 2025 -
Record Q2 Subscription Revenue of
, up$3.2 million from Q2 2025$2.4 million -
Q2 Gross Margin of
64.4% . Excluding in tariff refund impact, gross margin of$3.5 million 54.0% , up 270 basis points from Q2 2025 -
Q2 Net Loss of
. Excluding$0.6 million in tariff refund impact, net loss of$3.75 million , compared to net loss of$4.4 million in Q2 2025$37.4 million -
Record Q2 Adjusted EBITDA (non-GAAP) of
excluding$2.9 million in tariff refund impact, compared to$3.75 million in Q2 2025;$0.5 million of Adjusted EBITDA including tariff refund impact$6.7 million
“Owlet delivered an exceptional second quarter, with record quarterly revenue, gross profit, and adjusted EBITDA,” said Kurt Workman, Owlet’s President, Chief Executive Officer, and Co-Founder. “We are executing across each of our strategic growth areas, and it is showing up in our results – strong topline growth, standout international momentum, and continued Owlet360 subscription platform growth. We believe our biggest opportunity from here is growing subscribers, and that is exactly where the company is focused.”
“We believe our competitive position has never been stronger,” Workman continued. “We have the first and only FDA-cleared baby monitor on the market, and we set another record for market share in the quarter. Owlet has numerous growth levers – winning new families, building the subscription platform with Owlet360, expanding the opportunity in pediatric telehealth, and scaling internationally – all anchored by our unique pediatric dataset.”
“Our strategy from here is straightforward: firmly position Owlet as a data and services platform through subscription, win approximately one million new customers per year, and keep those families with us for at least two years. Over time, we believe executing that framework points toward a recurring base of more than one million subscribers, and a more durable, higher-value Owlet.”
Financial Results for the Second Quarter Ended June 30, 2026
Revenue for the second quarter of 2026 was
Subscription revenue for the second quarter of 2026 was
Cost of revenue for the second quarter of 2026 was
Subscription gross margin for the second quarter of 2026 was
Operating expenses, including stock-based compensation, were
Operating income was
Net loss was
Adjusted EBITDA (non-GAAP) was
Net loss per share was
Updated 2026 Financial Outlook
Our updated full year 2026 financial outlook below reflects the one-time IEEPA tariff refund recognized in the second quarter of 2026 and a measured view of the second half. Excluding the refund, our underlying expectations for the year are essentially unchanged.
-
Total Revenue is expected to be in the range of
to$118 , unchanged from our previous guidance.$122 million -
Gross Margin is expected to be in the range of
53% to55% , compared to our previous guidance of50% to52% . The increase reflects only the one-time tariff refund benefit to COGS recognized in the second quarter.$3.5 million -
Adjusted EBITDA is expected to be in the range of
to$10.75 , compared to our previous guidance of$12.75 million to$7 . The increase reflects only the one-time$9 million tariff refund benefit to Adjusted EBITDA recognized in the second quarter.$3.75 million
The outlook provided above constitutes forward-looking information within the meaning of applicable securities laws and is based on a number of assumptions and subject to a number of risks. See cautionary note regarding “Forward-looking Statements” below.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s expected financial performance, including the Company’s financial outlook, the timing, scope, and potential impact of global regulatory clearances, approvals, certifications and/or classifications, growth prospects, future operational efficiencies or results, the Company’s product, subscription, telehealth and artificial intelligence strategies, initiatives, and development plans, expectations regarding customer acquisition, retention, subscriber base targets, and long-term business model positioning, and changes in senior management. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “upcoming,” “outlook,” “guidance,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made and are susceptible to a number of risks, uncertainties and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by our forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to, (i) the commercial success of Owlet’s products, including its subscription services, and the Company’s ability to support, scale and maintain its subscription services; (ii) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of
Revision of Previously Issued Financial Statements
In connection with the preparation of the consolidated financial statements as of and for the three and six months ended June 30, 2026, management identified errors impacting historical interim and annual financial statements, which we determined not to be material, individually or in the aggregate, to any previously issued financial statements. These errors primarily relate to the overstatement of stock-based compensation expense due to valuation miscalculations underlying the employee stock purchase plan. We assessed the materiality of the errors on prior period interim and annual consolidated financial statements in accordance with the Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin No. 99, “Materiality,” and No. 108, codified in ASC 250, Accounting Changes and Error Corrections (“ASC 250”). Based on this assessment, in consideration of both quantitative and qualitative factors, we determined that the related impacts were not material, individually or in the aggregate, to any previously issued interim or annual financial statements. However, if the corrections were recorded in the three months ended June 30, 2026, they would be material to that period. As such, we will revise the previously issued consolidated financial statements for the three-month period ended March 31, 2026, in addition to quarterly and year-to-date periods for 2025 and for the annual periods ended December 31, 2025 and 2024. In conjunction with the revision, we will also correct certain other errors that were previously identified and disclosed and concluded to be immaterial, individually and in the aggregate, to the Company’s consolidated financial statements as of and for the relevant periods. This press release reflects revised prior period financial information for the periods presented herein to correct for these errors. The additional impacted periods noted above will be revised in our Form 10-Q for the quarterly period ended June 30, 2026, expected to be filed by August 14, 2026.
Disclosure Regarding Non-GAAP Financial Measures
In addition to the financial measures presented in this release in accordance with
The Company uses such non-GAAP financial measures as internal measures of business operating performance and as performance measures for benchmarking against the Company’s peers and competitors. The Company believes its presentation of adjusted EBITDA, adjusted net income (loss) and adjusted net income (loss) per share provides a meaningful perspective of the underlying operating performance of the Company’s current business and enables investors to better understand and evaluate its historical and prospective operating performance. The Company believes that this non-GAAP financial measure is an important supplemental measure of operating performance because it facilitates period-to-period comparisons of our operating performance by excluding certain items that management believes are not reflective of our core operating performance, highlighting trends in our business that may not otherwise be apparent when relying solely on GAAP financial measures. These non-GAAP financial measures should not be construed as indicative of our future operating results. The Company believes investors, analysts and other interested parties use adjusted EBITDA, adjusted net income (loss) and adjusted net income (loss) per share in evaluating issuers, and the presentation of these measures facilitates a comparative assessment of the Company’s operating performance in addition to the Company’s performance based on GAAP results.
The Company’s non-GAAP financial measures should not be considered as an alternative to net income (loss) or net income (loss) per share as a measure of financial performance or any other performance measure derived in accordance with GAAP and should not be construed as an inference that the Company’s future results will be unaffected by unusual or non-recurring items.
Adjusted EBITDA is defined as net income (loss) adjusted for income tax provision, interest expense, net, depreciation and amortization, impairment of intangible assets, common stock warrant liability adjustment, stock-based compensation, charges related to certain legal matters, restructuring costs, and loss on debt extinguishment.
Adjusted net income (loss) is defined as net income (loss) adjusted for impairment of intangible assets, common stock warrant liability adjustment, stock-based compensation, charges related to certain legal matters, restructuring costs, and loss on debt extinguishment. Adjusted net income (loss) per share is defined as adjusted net income (loss) divided by the basic weighted-average number of shares of common stock outstanding.
Adjusted EBITDA, adjusted net income (loss) and adjusted net income (loss) per share are not recognized terms under GAAP, and the Company’s presentation of these non-GAAP measures does not replace the presentation of the Company’s financial results in accordance with GAAP. Because all companies do not use adjusted EBITDA, adjusted net income (loss) and adjusted net income (loss) per share (and similarly titled financial measures) in the same way, those measures as used by other companies may not be consistent with the way the Company calculates such measures. The non-GAAP financial measures included in this release should not be construed as substitutes for or better indicators of the Company’s performance than the most directly comparable GAAP financial measures. See the reconciliation tables that accompany this release for additional information regarding certain of the non-GAAP financial measures included herein.
A reconciliation of the Company's guidance contained in this press release with respect to non-GAAP financial measures to the most directly comparable GAAP financial measure cannot be provided without unreasonable efforts and is not provided herein because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, the amounts of which could be material.
Conference Call and Webcast Information
Owlet will host a conference call and webcast today, August 11, 2026, at 4:30 p.m. ET to discuss these results and provide a business update.
Participants may access the call at 833-461-5787 (domestic) or 585-542-9983 (international) and reference Meeting ID 883284960. A simultaneous webcast may be accessed online at the Events section of Owlet’s Investor Relations website at investors.owletcare.com. A replay will be available on the Investor Relations website shortly after the webcast concludes.
About Owlet, Inc.
Owlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer
Owlet, Inc. Condensed Consolidated Balance Sheets - Preliminary, Unaudited1 (in millions) |
||||||
Assets |
|
June 30, 2026 |
|
December 31, 2025 |
||
Current assets: |
|
|
|
|
||
Cash and cash equivalents |
|
$ |
30.9 |
|
$ |
35.5 |
Restricted cash |
|
|
5.6 |
|
|
5.6 |
Accounts receivable, net |
|
|
33.1 |
|
|
22.9 |
Inventory |
|
|
15.7 |
|
|
15.3 |
Prepaid expenses and other current assets |
|
|
3.0 |
|
|
2.7 |
Total current assets |
|
|
88.3 |
|
|
81.9 |
Property and equipment, net |
|
|
0.8 |
|
|
0.3 |
Intangible assets, net |
|
|
2.0 |
|
|
1.4 |
Other assets |
|
|
2.4 |
|
|
2.0 |
Total assets |
|
$ |
93.6 |
|
$ |
85.6 |
Liabilities, Mezzanine Equity, and Stockholders’ Equity |
|
|
|
|
||
Current liabilities: |
|
|
|
|
||
Accounts payable |
|
$ |
12.1 |
|
$ |
12.0 |
Accrued and other expenses |
|
|
21.8 |
|
|
19.4 |
Current portion of deferred revenue |
|
|
2.8 |
|
|
2.3 |
Line of credit |
|
|
17.1 |
|
|
6.9 |
Current portion of long-term and other debt |
|
|
— |
|
|
3.6 |
Total current liabilities |
|
|
53.8 |
|
|
44.2 |
Long-term debt, net |
|
|
— |
|
|
2.5 |
Common stock warrant liabilities |
|
|
0.8 |
|
|
3.3 |
Other long-term liabilities |
|
|
0.1 |
|
|
0.2 |
Total liabilities |
|
|
54.7 |
|
|
50.2 |
Total mezzanine equity |
|
|
15.7 |
|
|
16.4 |
Total stockholders’ equity |
|
|
23.1 |
|
|
19.0 |
Total liabilities, mezzanine equity, and stockholders' equity |
|
$ |
93.6 |
|
$ |
85.6 |
1 |
Amounts may not sum due to rounding |
Owlet, Inc. Condensed Consolidated Statements of Cash Flows - Preliminary, Unaudited1 (in millions) |
|||||||
|
Six Months Ended June 30, |
||||||
|
2026 |
|
2025 |
||||
Net cash used in operating activities |
$ |
(5.3 |
) |
|
$ |
(8.3 |
) |
Net cash used in investing activities |
|
(1.4 |
) |
|
|
(0.2 |
) |
Net cash provided by financing activities |
|
2.0 |
|
|
|
9.9 |
|
Net change in cash, cash equivalents, and restricted cash |
$ |
(4.6 |
) |
|
$ |
1.4 |
|
1 |
Amounts may not sum due to rounding |
Owlet, Inc. Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - Preliminary, Unaudited1 (in millions, except share and per share amounts) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||||||
Revenue: |
|
|
|
|
|
|
|
||||||||
Hardware |
$ |
30.6 |
|
|
$ |
25.2 |
|
|
$ |
50.4 |
|
|
$ |
46.4 |
|
Subscription |
|
3.2 |
|
|
|
0.9 |
|
|
|
5.9 |
|
|
|
1.3 |
|
Total revenue |
|
33.9 |
|
|
|
26.1 |
|
|
|
56.3 |
|
|
|
47.6 |
|
Cost of revenue: |
|
|
|
|
|
|
|
||||||||
Hardware |
|
11.0 |
|
|
|
12.5 |
|
|
|
20.4 |
|
|
|
22.1 |
|
Subscription |
|
1.0 |
|
|
|
0.2 |
|
|
|
1.9 |
|
|
|
0.4 |
|
Total cost of revenue |
|
12.0 |
|
|
|
12.7 |
|
|
|
22.3 |
|
|
|
22.5 |
|
Gross profit |
|
21.8 |
|
|
|
13.4 |
|
|
|
34.1 |
|
|
|
25.2 |
|
Operating expenses: |
|
|
|
|
|
|
|
||||||||
General and administrative |
|
9.6 |
|
|
|
7.0 |
|
|
|
18.8 |
|
|
|
14.1 |
|
Sales and marketing |
|
6.0 |
|
|
|
4.3 |
|
|
|
10.4 |
|
|
|
8.3 |
|
Research and development |
|
4.6 |
|
|
|
3.7 |
|
|
|
8.5 |
|
|
|
6.6 |
|
Total operating expenses |
|
20.1 |
|
|
|
15.1 |
|
|
|
37.7 |
|
|
|
29.0 |
|
Operating income (loss) |
|
1.7 |
|
|
|
(1.7 |
) |
|
|
(3.7 |
) |
|
|
(3.9 |
) |
Other income (expense): |
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
(0.7 |
) |
|
|
(1.0 |
) |
|
|
(1.4 |
) |
|
|
(2.0 |
) |
Common stock warrant liability adjustment |
|
(0.1 |
) |
|
|
(34.8 |
) |
|
|
2.5 |
|
|
|
(28.1 |
) |
Other income (expense), net |
|
0.7 |
|
|
|
— |
|
|
|
0.9 |
|
|
|
— |
|
Loss on debt extinguishment |
|
(2.2 |
) |
|
|
— |
|
|
|
(2.2 |
) |
|
|
— |
|
Total other income (expense), net |
|
(2.4 |
) |
|
|
(35.7 |
) |
|
|
(0.2 |
) |
|
|
(30.0 |
) |
Loss before income tax provision |
|
(0.6 |
) |
|
|
(37.4 |
) |
|
|
(3.8 |
) |
|
|
(33.8 |
) |
Income tax provision |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Net loss and comprehensive loss |
$ |
(0.6 |
) |
|
$ |
(37.4 |
) |
|
$ |
(3.9 |
) |
|
$ |
(33.9 |
) |
Accretion on convertible preferred stock |
|
(0.8 |
) |
|
|
(0.8 |
) |
|
|
(1.7 |
) |
|
|
(1.7 |
) |
Allocation of accretion on convertible preferred stock to redeemable common stock |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
0.1 |
|
Accretion on redeemable common stock |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Allocation of net loss attributable to redeemable common stockholders |
|
— |
|
|
|
1.3 |
|
|
|
— |
|
|
|
1.2 |
|
Net loss attributable to redeemable common stockholders |
$ |
— |
|
|
$ |
(1.3 |
) |
|
$ |
— |
|
|
$ |
(1.2 |
) |
Net loss attributable to common stockholders |
$ |
(1.5 |
) |
|
$ |
(37.0 |
) |
|
$ |
(5.5 |
) |
|
$ |
(34.4 |
) |
|
|
|
|
|
|
|
|
||||||||
Net loss per share attributable to redeemable common stockholders |
|
|
|
|
|
|
|
||||||||
Basic |
$ |
(0.01 |
) |
|
$ |
(2.31 |
) |
|
$ |
(0.13 |
) |
|
$ |
(2.13 |
) |
Diluted |
$ |
(0.01 |
) |
|
$ |
(2.31 |
) |
|
$ |
(0.13 |
) |
|
$ |
(2.13 |
) |
Weighted-average number of shares outstanding used to compute net loss per share attributable to redeemable common stockholders |
|
|
|
|
|
|
|
||||||||
Basic |
|
252,500 |
|
|
|
562,500 |
|
|
|
307,610 |
|
|
|
562,500 |
|
Diluted |
|
252,500 |
|
|
|
562,500 |
|
|
|
307,610 |
|
|
|
562,500 |
|
|
|
|
|
|
|
|
|
||||||||
Net loss per share attributable to common stockholders |
|
|
|
|
|
|
|
||||||||
Basic |
$ |
(0.05 |
) |
|
$ |
(2.35 |
) |
|
$ |
(0.20 |
) |
|
$ |
(2.21 |
) |
Diluted |
$ |
(0.05 |
) |
|
$ |
(2.35 |
) |
|
$ |
(0.29 |
) |
|
$ |
(2.21 |
) |
|
|
|
|
|
|
|
|
||||||||
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders |
|
|
|
|
|
|
|
||||||||
Basic |
|
28,514,423 |
|
|
|
15,716,376 |
|
|
|
27,968,200 |
|
|
|
15,550,751 |
|
Diluted |
|
28,514,423 |
|
|
|
15,716,376 |
|
|
|
28,077,338 |
|
|
|
15,550,751 |
|
1 |
Amounts may not sum due to rounding |
Owlet, Inc. Reconciliation of GAAP to Non-GAAP Measures - Preliminary, Unaudited1 (in millions, except share and per share amounts) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||||||
GAAP net loss |
$ |
(0.6 |
) |
|
$ |
(37.4 |
) |
|
$ |
(3.9 |
) |
|
$ |
(33.9 |
) |
Income tax provision |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Interest expense, net |
|
0.7 |
|
|
|
1.0 |
|
|
|
1.4 |
|
|
|
2.0 |
|
Depreciation and amortization |
|
0.2 |
|
|
|
0.1 |
|
|
|
0.4 |
|
|
|
0.2 |
|
Impairment of intangible assets |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Common stock warrant liability adjustment |
|
0.1 |
|
|
|
34.8 |
|
|
|
(2.5 |
) |
|
|
28.1 |
|
Stock-based compensation |
|
3.3 |
|
|
|
1.5 |
|
|
|
6.7 |
|
|
|
3.1 |
|
Charges related to certain legal matters |
|
— |
|
|
|
0.5 |
|
|
|
— |
|
|
|
1.4 |
|
Restructuring costs |
|
0.7 |
|
|
|
— |
|
|
|
0.7 |
|
|
|
— |
|
Loss on debt extinguishment |
|
2.2 |
|
|
|
— |
|
|
|
2.2 |
|
|
|
— |
|
Non-GAAP Adjusted EBITDA |
$ |
6.7 |
|
|
$ |
0.5 |
|
|
$ |
5.1 |
|
|
$ |
0.9 |
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||||||
GAAP net loss |
$ |
(0.6 |
) |
|
$ |
(37.4 |
) |
|
$ |
(3.9 |
) |
|
$ |
(33.9 |
) |
Non-GAAP adjustments: |
|
|
|
|
|
|
|
||||||||
Impairment of intangible assets |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Common stock warrant liability adjustment |
|
0.1 |
|
|
|
34.8 |
|
|
|
(2.5 |
) |
|
|
28.1 |
|
Stock-based compensation |
|
3.3 |
|
|
|
1.5 |
|
|
|
6.7 |
|
|
|
3.1 |
|
Charges related to certain legal matters |
|
— |
|
|
|
0.5 |
|
|
|
— |
|
|
|
1.4 |
|
Restructuring costs |
|
0.7 |
|
|
|
— |
|
|
|
0.7 |
|
|
|
— |
|
Loss on debt extinguishment |
|
2.2 |
|
|
|
— |
|
|
|
2.2 |
|
|
|
— |
|
Non-GAAP adjusted net income (loss) |
$ |
5.7 |
|
|
$ |
(0.6 |
) |
|
$ |
3.3 |
|
|
$ |
(1.3 |
) |
Non-GAAP adjusted net income (loss) per share |
$ |
0.20 |
|
|
$ |
(0.04 |
) |
|
$ |
0.12 |
|
|
$ |
(0.08 |
) |
Weighted-average number of shares outstanding attributable to common stockholders, basic |
|
28,514,423 |
|
|
|
15,716,376 |
|
|
|
27,968,200 |
|
|
|
15,550,751 |
|
1 |
Amounts may not sum due to rounding |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260811059604/en/
Owlet Media Contacts:
pr@owletcare.com
owlet@hannahcranstonmedia.com
Owlet Investor Contact:
ir@owletcare.com
Source: Owlet, Inc.